Project Grant R21AI190670
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $189K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
- The federal Project Grant award for "BIOPROTAC-MEDIATED DEGRADATION OF HIV-1 REV" was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $227,588 award, with a period of performance from August 1, 2025 to July 31, 2027, supports research to develop a protein-based proteolysis targeting chimera (BIOPROTAC) strategy to degrade the HIV-1 Rev protein, which is critical for the HIV-1...
- The federal Project Grant award R01AI191807, with $507,792.00 in funding, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to determine the role of the precursor HIV-1 protease (PR) in the development of drug resistance to protease inhibitors (PIs). Key objectives include assessing how mutations in PR or the cleavage site influence precursor and mature PR function, evaluating...
- This Project Grant award of $962,973.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop and evaluate a comprehensive curriculum on HIV prevention and implementation science for pharmacy schools in the southern United States. The project, titled "Pharmacists for Prevention (P4P): Harnessing the Role of Pharmacists in Ending the HIV Epidemic through Collaboration with Pharmacy Schools," will be...
- This $624,902 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the impact of the HIV accessory protein Vpr on epigenetic remodeling and viral persistence in myeloid cells. The 5-year project, starting on Apr 23, 2025, will focus on characterizing how Vpr induces epigenetic changes to facilitate sustained HIV transcription and latency reactivation, as well as...
- This federal Project Grant award for $657,907 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support a 5-year longitudinal analysis to understand the impact of expanding pharmacists' scope of practice on the uptake and retention of pre-exposure prophylaxis (PrEP) for HIV prevention. The project aims to integrate multiple data sources, including policy, census, survey, and medical claims data, to...
- This $147,486 Project Grant was awarded on January 10, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research by Case Western Reserve University to investigate how the N6-methyladenosine (m6A) RNA modification affects the post-transcriptional processing of human immunodeficiency virus (HIV) transcripts. The research aims to elucidate the role of m6A in the...
- This $118,488 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) on January 20, 2025, supports research to develop HIV-resistant hematopoietic stem cells through targeted base editing. The project aims to identify genetic mutations in the CCR5 and CXCR4 co-receptors that can prevent HIV entry into CD4 cells while maintaining the central functions of these proteins in hematopoiesis. The research involves...
- This Project Grant award of $800,389.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The proposed treatment combines soluble IL-15/IL-15RA-FC with a TGF-β pathway blockade and therapeutic vaccination to enhance and restore anti-viral immunity, leading to sustained viral remission...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $3,554,273 to the Fred Hutchinson Cancer Center in Seattle, WA to assess the impact of oral pre-exposure prophylaxis (PrEP) on the pharmacokinetics of monoclonal antibodies and vaccine-induced antibodies among women vulnerable to HIV-1. The key objectives of this 4-year award are to: 1) Determine whether oral...
- The federal Project Grant award for "PHYLOGENETICS, CAUSAL INFERENCE, AND MODEL DIAGNOSTICS FOR LONGITUDINAL STUDIES OF INFECTIOUS DISEASE TRANSMISSION AND CONTROL" was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The $537,861 award will support research to extend statistical methods for studying disease transmission in households and other close contact groups....